Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Corcept Therapeutics Incorporated | Relacorilant plus ABRAXANE (nab-paclitaxel) - (ROSELLA) | Ovarian cancer | PDUFA | Ongoing | Intravenous | Oncology |
| Corcept Therapeutics Incorporated | Miricorilant - (MONARCH) | Nonalcoholic steatohepatitis (NASH) | Phase 2b | Ongoing | Oral | Gastroenterology |
| Corcept Therapeutics Incorporated | Miricorilant - (GRATITUDE 2) | Long-standing antipsychotic-induced weight gain (APIWG) | Phase 2 | Trial Discontinued | Oral | Psychiatric |
| Corcept Therapeutics Incorporated | Korlym - (CATALYST) | Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes | Phase 3 | Data Released | Oral | Endocrinology |
| Corcept Therapeutics Incorporated | Dazucorilant (DAZALS) | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Data Released | Oral | Neurology |
| Corcept Therapeutics Incorporated | Miricorilant - (GRATITUDE) | Antipsychotic-induced weight gain (APIWG) | Phase 2 | Trial Completed | Oral | Psychiatric |
| Corvus Pharmaceuticals Inc. | Soquelitinib - (CPI-818) | Peripheral T-cell lymphoma (PTCL) | Phase 3 | Ongoing | Oral | Oncology |
| Corvus Pharmaceuticals Inc. | Soquelitinib - (CPI-818) | Autoimmune Lymphoproliferative Syndrome (ALPS) | Phase 2 | Ongoing | oral | Immunology |
